Pulvules® Vancocin® HCl (Vancomycin Hydrochloride Capsules, USP) contain chromatographically purified vancomycin hydrochloride, a tricyclic glycopeptide antibiotic derived from
Nocardia orientalis), which has the chemical formula C66H75Cl2N9O24·HCl.
Vancocin HCl Pulvules may be administered orally for treatment of enterocolitis caused by
(including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by
C. difficile. Parenteral administration of Vancocin HCl is not effective for the above indications; therefore, Vancocin HCl must be given orally for these indications. Orally administered Vancocin HCl is not effective for other types of infection.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancocin HCl and other antibacterial drugs, Vancocin HCl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Media Articles Related to Vancocin (Vancomycin)
Vancomycin-Resistant Enterococci (VRE)
Source: MedicineNet ICU Psychosis Specialty [2014.01.22]
Title: Vancomycin-Resistant Enterococci (VRE)
Category: Diseases and Conditions
Created: 5/8/2007 12:00:00 AM
Last Editorial Review: 1/22/2014 12:00:00 AM
Zyvox® shows cost savings for treatment of skin infections
Source: The Doctors Lounge - Infections
Oral Zyvox® shows cost savings for outpatient treatment of skin and other infections when compared to vancomycin.
Published Studies Related to Vancocin (Vancomycin)
Health economic evaluation of patients treated for nosocomial pneumonia caused by
methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter
randomized clinical trial of vancomycin and linezolid. 
PURPOSE: Results from studies comparing health care resource use (HCRU), costs of
treatment, and cost-effectiveness of linezolid compared with vancomycin therapy
in the treatment of hospitalized patients with methicillin-resistant
Staphylococcus aureus (MRSA) nosocomial pneumonia are limited in the published
Resolution of Clostridium difficile-associated diarrhea in patients with cancer
treated with fidaxomicin or vancomycin. 
difficile-associated diarrhea (CDAD). Little is known about treatment response... CONCLUSION: For patients with cancer, fidaxomicin treatment was superior to
Randomised clinical trial: vancomycin or metronidazole in patients with primary
sclerosing cholangitis - a pilot study. 
in patients with PSC... CONCLUSIONS: Both vancomycin and metronidazole demonstrated efficacy; however,
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and
Candida species in patients treated with fidaxomicin versus vancomycin for
Clostridium difficile infection. 
Fidaxomicin causes less disruption of anaerobic microbiota during treatment of
Clostridium difficile infection (CDI) than vancomycin and has activity against
many vancomycin-resistant enterococci (VRE). In conjunction with a multicenter
randomized trial of fidaxomicin versus vancomycin for CDI treatment, we tested
the hypothesis that fidaxomicin promotes VRE and Candida species colonization
less than vancomycin...
Meta-analysis of randomized controlled trials of vancomycin for the treatment of
patients with gram-positive infections: focus on the study design. 
of other antibiotics for the treatment of gram-positive infections... CONCLUSION: On the basis mainly of data from open-label trials, vancomycin is a
Clinical Trials Related to Vancocin (Vancomycin)
Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation [Completed]
This is a randomized 2-arm study to compare two different times of giving the drug
vancomycin. Half of the patients will begin vancomycin two days before a bone marrow
transplant. The other half will get it as soon as they have the first fever.
Streptococci are bacteria that live in one's mouth and gut. These bacteria can escape into
the blood when the lining of the mouth and gut weakens from cancer therapy. This can make
the person who is undergoing a bone marrow transplant very sick. All patients who get this
infection are treated with antibiotics. Vancomycin is one drug that is used to treat this
bloodstream infection once it is diagnosed. Studies have shown that giving vancomycin before
a bone marrow transplant seems to prevent this infection. However, giving vancomycin too
soon may increase the chance that the kidneys will be irritated. It may also increase the
chance that other bacteria will become resistant to this drug. We, the investigators at
Memorial Sloan-Kettering Cancer Center, do not know if waiting to start vancomycin until the
patient has a first fever can also prevent this infection.
Intracolonic Vancomycin Therapy in Severe C. Diff Colitis [Recruiting]
Clostridium difficile is a bacteria that can infect the colon and cause severe diarrhea in
patients after recent antibiotic use. The current standard of care treatment for severe C.
diff. consists of oral vancomycin and/or intravenous metronidazole. When treatment is
unsuccessful, it can lead to need for removal of the entire colon or even death. In fact,
mortality rates in the literature range from 11-37% for C. diff. The most commonly quoted
mortality rate is 14% for severe infection. It is believed that the failure of treatment
may stem from an adynamic ileus (paralysis of the small bowel). This ileus may prevent the
oral vancomycin from reaching the colon and therefore it does not treat the problem.
Vancomycin functions by direct contact with the colon. Therefore, if the vancomycin is
instilled directly into the colon, it can come into contact with and be its intended target.
: The objective of the study is to improve treatment of severe C. diff. colitis . C.
diff. infection is defined as severe if there is evidence of ileus accompanied by any one of
the following: fever greater than 38. 30C, , acidemia, serum albumin less than 2. 5, or white
blood cell count greater than 14,000.
Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients [Recruiting]
The investigators hope to learn 1) if the addition of prophylaxis with vancomycin will
decrease the rate of cefazolin non-susceptible SSI's, in high risk population 2) to develop
better understanding of vancomycin and cefazolin pharmacokinetics in children undergoing
cardiopulmonary bypass 3) to assess the barriers to vancomycin dosing peri-operatively 4) to
assess side effects and risks associated with peri-operative vancomycin administration. This
will allow us to improve patient care by better understanding the benefits or the risks of
peri-operative vancomycin administration and potentially decrease cefazolin-resistant
surgical site infections.
In addition, this study gives us the opportunity to evaluate cefazolin and vancomycin
pharmacokinetics on children on CPB.
The investigators will take blood samples from 20 patients. In 10 patients the investigators
will do Cefazolin pK analysis and in the other 10 the investigators will do pK Vancomycin
analysis. For the remainder of 292 patients, only prospective chart review will be done to
determine the incidence of SSI's.
This data will be compared with 936 controls who received only Cefazolin pre-operatively as
prophylaxis for SSI's.
Loading Vancomycin Doses in the Emergency Department [Recruiting]
In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently
there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the
IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic
levels more rapidly. It has been hypothesized that if therapeutic levels are reached more
rapidly then patients will in turn have better clinical outcomes and that the development of
resistant organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA)
has emerged as one of the most deadly pathogens that are currently plaguing our patient
population. Vancomycin is one of only a few antibiotics that are effective for treating
MRSA. It is imperative that the ED physicians consistently and correctly dose vancomycin in
order to give the patients the best chance to fight infection while helping to prevent
further resistance in this already highly resistant organism. It is believed this study will
reveal that the new dosing recommendations by the IDSA will lead to the achievement of
therapeutic levels more rapidly. This information will in turn help to convince ED
physicians that a change in current clinical practice is warranted and ultimately lead to
better clinically outcomes for the patients.
Pharmacokinetics of Vancomycin in the ICU in Renal Replacement Therapy [Recruiting]
This study is an observational analysis that monitors the effect of different dialysis
methods on vancomycin levels when patients are critically ill. No changes are made to
therapy based on levels, but levels are checked more frequently than normal. The primary
dialysis methods being studied are SLED (slow-low efficiency daily) dialysis and
intermittent hemodialysis. Vancomycin is the only medication being evaluated in this study.
This study will provide detailed information on how to dose vancomycin in patients that are
on dialysis in the intensive care unit.